Prostatype Genomics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-44.5	-41.05	-41.44	-29.09	-15.63
Depreciation & Amortization	-	0.12	0.02	0.05	0.09
Other Amortization	-	1.86	1.86	1.86	-
Other Operating Activities	7.72	-1.06	0.6	0	-
Change in Accounts Receivable	0.26	-0.24	0.98	-1.42	0.13
Change in Inventory	0.02	0.11	-0.02	-	0.21
Change in Other Net Operating Assets	12.7	-4.44	8.86	0.91	-0.88
Operating Cash Flow	-23.8	-44.71	-29.14	-27.69	-16.08
Capital Expenditures	-0.26	-0.29	-0.08	-	-
Sale (Purchase) of Intangibles	-13.18	-7.58	-8.49	-	-2.5
Investment in Securities	0.08	-0.49	-0	-	-
Investing Cash Flow	-13.36	-8.36	-8.57	-	-2.5
Long-Term Debt Issued	10.55	8.83	16.2	-	23.25
Total Debt Issued	10.55	8.83	16.2	-	23.25
Long-Term Debt Repaid	-5.32	-15.23	-5.4	-0.4	-0.2
Total Debt Repaid	-5.32	-15.23	-5.4	-0.4	-0.2
Net Debt Issued (Repaid)	5.23	-6.4	10.8	-0.4	23.05
Issuance of Common Stock	31.6	66.15	18.11	19.25	-
Other Financing Activities	0	-	-	-	-
Financing Cash Flow	36.83	59.75	28.91	18.85	23.05
Foreign Exchange Rate Adjustments	-0.02	0.05	-0.01	-	-
Miscellaneous Cash Flow Adjustments	-	-	-0	-	-
Net Cash Flow	-0.35	6.74	-8.81	-8.84	4.47
Free Cash Flow	-24.06	-44.99	-29.21	-27.69	-16.08
Free Cash Flow Margin	-4029.98%	-2345.88%	-783.61%	-4054.61%	-640.66%
Free Cash Flow Per Share	-	-31.89	-361.46	-1521.34	-1137.23
Levered Free Cash Flow	-22.05	-16.09	-43.78	-16.8	-12.72
Unlevered Free Cash Flow	-21.05	-15.04	-42.82	-16.55	-12.67
Change in Working Capital	12.98	-4.57	9.82	-0.51	-0.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.